The article, "transcatheter aortic valve replacement in congenital heart disease", was reviewed.The article presented a case study of a 47-year-old male patient with tetralogy of fallot for which he underwent a total of 5 open heart surgeries.It was reported that on an unknown date, a 27mm unknown biocor valve was implanted for aortic valve replacement procedure.The patient later presented on an unknown date with moderate to sever aortic stenosis (peak gradient was 51mmhg and mean gradient was 30mmhg), and no aortic regurgitation on transthoracic echocardiography (tte).A decision was made to perform a transcatheter valve-in-valve procedure with a 26mm edwards sapient s3 valve.The article concluded that transcatheter aortic valve replacement (tavr) can be an effective intervention in congenital heart disease (chd) in select clinical scenarios, proving both feasible and safe with good short-term outcomes in this small case series.In high surgical risk, it can be used as a bridge to recovery, future surgery, transplantation, or palliation.There is an important need for large prospective clinical trials of tavr in chd.[the primary and corresponding author was joanna ghobrial, department of cardiovascular medicine, cleveland clinic, 9500 euclid avenue, cleveland ohio 99175, usa, with corresponding e-mail: ghobrij@ccf.Org].
|
B3 - date of event is estimated.D4 - the udi number is not known as the part and lot numbers were not provided.As reported in a research article, transcatheter aortic valve replacement in congenital heart disease.A more comprehensive assessment could not be performed as the event was non-contemporaneously reported through a literature review and no device was received for analysis.Based on the information received, the cause of the reported incident could not be conclusively determined.
|